Thursday, October 20, 2016 8:23:17 AM
HedgePath Pharmaceuticals Announces Further Positive Interim Data in its Phase II(b) Cancer Trial
18 subjects with Basal Cell Carcinoma Nevus Syndrome who had 231 surgically eligible tumors complete 16 weeks of dosing with SUBA™-Itraconazole
Second interim analysis shows a statistically significant mean target tumor burden reduction (P<0.0001) and 11 of 18 trial subjects to date achieving a 30% or greater reduction in target tumor burden
Full Article: http://www.prnewswire.com/news-releases/hedgepath-pharmaceuticals-announces-further-positive-interim-data-in-its-phase-iib-cancer-trial-300348148.html
Recent INTI News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 11:02:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/18/2023 01:54:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/29/2023 07:49:19 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/29/2023 06:42:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2023 06:33:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 01:15:19 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM